Financial toxicity due to breast cancer treatment in low- and middle-income countries: evidence from Vietnam
Journal – Supportive Care in Cancer
Article type – Journal research article – Clinical research
Publication date – Apr – 2021
Authors – Tran Thu Ngan, Hoang Van Minh, Michael Donnelly , Ciaran O’Neill
Keywords – Breast Cancer, Cost of treatment, Financial toxicity/hardship, LMICs, vietnam
Open access – Yes
Speciality – General surgery, Surgical oncology
World region South-eastern Asia
Language – English
Submitted to the One Surgery Index on April 27, 2021 at 12:41 am
This study examined the financial toxicity faced by breast cancer (BC) patients in Vietnam and the factors associated with the risk and degree of that toxicity.
A total of 309 BC patients/survivors completed an online survey (n=209) or a face-to-face interview (n=100) at two tertiary hospitals. Descriptive statistics and χ2 tests were used to identify and analyse the forms and degree of financial toxicity faced by BC patients/survivors. A Cragg hurdle model assessed variation in risk and the degree of financial toxicity due to treatment.
41% of respondents faced financial toxicity due to BC treatment costs. The mean amount of money that exceeded BC patients/survivors’ ability to pay was 153 million Vietnamese Dong (VND) ($6602) and ranged from 2.42 million VND to 1358 million VND ($104–58,413). A diagnosis at stage II or III of BC was associated with 16.0 and 18.0 million VND (~$690–777) more in the degree of financial toxicity compared with patients who were diagnosed at stage 0/I, respectively. Being retired or married or having full (100%) health insurance was associated with a decrease in the degree of financial toxicity.
A significant proportion of Vietnamese BC patients/survivors face serious financial toxicity due to BC treatment costs. There is a need to consider the introduction of measures that would attenuate this hardship and promote uptake of screening for the reduction in financial toxicity as well as the health gains it may achieve through earlier detection of cancer.
OSI Number – 21039